Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient

Area of Science:

• Pharmacology
• Neuroscience
• Clinical Medicine

Background:

• Neuroleptic malignant syndrome (NMS) is a rare, life-threatening complication associated with antipsychotic medications.
• While atypical neuroleptics are generally considered to have a lower risk than typical neuroleptics, their increasing use necessitates ongoing surveillance.
• Understanding NMS pathophysiology is crucial for managing patients on modern psychopharmacotherapy.

Observation:

• This report describes three distinct episodes of NMS that met the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria.
• The NMS episodes occurred during treatment with specific atypical antipsychotics: clozapine, risperidone, and amisulpride.
• These cases presented with several atypical features that warrant further investigation.

Findings:

• The observed NMS episodes, while fulfilling DSM-IV criteria, exhibited atypical characteristics.
• The specific atypical neuroleptics involved were clozapine, risperidone, and amisulpride.
• Analysis of these atypical features may provide new insights into NMS pathogenesis.

Implications:

• Increased vigilance for NMS is recommended, even with atypical antipsychotics.
• Further research into the pathophysiological mechanisms underlying atypical NMS presentations is needed.
• This study contributes to the understanding of rare but severe adverse drug reactions in psychopharmacology.